brain scanning technology to commercial psychedelics trials

A new partnership announced between Clerkenwell Health and MYndspan brings brain scanning technology to  commercial psychedelics trials .   The partnership enables medical researchers to utilize MYndspan's magnetoencephalography (MEG) brain scanning technology, making it the first commercial MEG scanner available for commercial clinical trials. Clerkenwell Health  is a psychedelic-specialist clinical research organization, claiming to be Europe’s first commercial facility dedicated to psychedelic-assisted therapies. There are 81 upcoming clinical trial completions globally in 2023, with 46 of them commercially sponsored or affiliated. The partnership will offer valuable insights into the drugs' mechanisms of action and effectiveness for Clerkenwell Health's clients. Psychedelics can potentially address complex mental health conditions such as depression and PTSD. The partnership solidifies London's role as the center of Europe's medical psychedelics sector. Clerkenwell Health has signed agreements with Canadian and US-based drug developers, including Mindset Pharma and PharmAla Biotech, to test treatments for various mental health conditions. The use of psychedelics in therapeutic settings has gained attention for its potential in treating  mental health disorders .